Transforming cancer treatment and advancing new therapies through empowered science.

Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to... 
Read more

NASDAQ | SGEN (Common Stock)

$66.26

 0.67 (1.00%)

High$68.80
Low$65.63
Volume360,429
Market Cap$9,474,118,597

12/09/16  1:54 p.m. ET

Minimum 20 minute delay

Latest Investor Information

Press Releases

Seattle Genetics and Bristol-Myers Squibb Highlight First Data from Phase 1/2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) in Combination with Opdivo (nivolumab) in Relapsed or Refractory Hodgkin Lymphoma at ASH Annual Meeting 12/05/16

Read more

Seattle Genetics Highlights Long-Term Follow-Up Data from ADCETRIS® (Brentuximab Vedotin) in T-Cell Lymphomas at ASH Annual Meeting 12/05/16

Read more

Events

Investor and Analyst Event at the American Society of Hematology (ASH) Annual Meeting12/05/16 8:15 p.m. PTView eventCredit Suisse 25th Annual Healthcare Conference11/08/16 12:00 p.m. ETView event
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources